ATXS
Price
$6.47
Change
+$0.65 (+11.17%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
365.69M
57 days until earnings call
RCUS
Price
$9.91
Change
+$0.50 (+5.31%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
1.05B
62 days until earnings call
Ad is loading...

ATXS vs RCUS

Header iconATXS vs RCUS Comparison
Open Charts ATXS vs RCUSBanner chart's image
Astria Therapeutics
Price$6.47
Change+$0.65 (+11.17%)
Volume$16.41K
Capitalization365.69M
Arcus Biosciences
Price$9.91
Change+$0.50 (+5.31%)
Volume$7.73K
Capitalization1.05B
ATXS vs RCUS Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. RCUS commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and RCUS is a Buy.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (ATXS: $5.83 vs. RCUS: $9.41)
Brand notoriety: ATXS and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 115% vs. RCUS: 158%
Market capitalization -- ATXS: $365.69M vs. RCUS: $1.05B
ATXS [@Biotechnology] is valued at $365.69M. RCUS’s [@Biotechnology] market capitalization is $1.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATXS and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while RCUS’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • RCUS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ATXS and RCUS are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -4.43% price change this week, while RCUS (@Biotechnology) price change was -10.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.64%. For the same industry, the average monthly price growth was -8.11%, and the average quarterly price growth was -7.39%.

Reported Earning Dates

ATXS is expected to report earnings on May 08, 2025.

RCUS is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+0.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($1.05B) has a higher market cap than ATXS($366M). ATXS YTD gains are higher at: -34.787 vs. RCUS (-36.803). ATXS has higher annual earnings (EBITDA): -100.97M vs. RCUS (-257M). RCUS has more cash in the bank: 1.09B vs. ATXS (344M). ATXS has less debt than RCUS: ATXS (5.64M) vs RCUS (58M). RCUS has higher revenues than ATXS: RCUS (263M) vs ATXS (0).
ATXSRCUSATXS / RCUS
Capitalization366M1.05B35%
EBITDA-100.97M-257M39%
Gain YTD-34.787-36.80395%
P/E RatioN/AN/A-
Revenue0263M-
Total Cash344M1.09B32%
Total Debt5.64M58M10%
FUNDAMENTALS RATINGS
ATXS vs RCUS: Fundamental Ratings
ATXS
RCUS
OUTLOOK RATING
1..100
675
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9493
PRICE GROWTH RATING
1..100
9391
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (59) in the Pharmaceuticals Major industry is in the same range as ATXS (62) in the Biotechnology industry. This means that RCUS’s stock grew similarly to ATXS’s over the last 12 months.

RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to ATXS’s over the last 12 months.

RCUS's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as ATXS (94) in the Biotechnology industry. This means that RCUS’s stock grew similarly to ATXS’s over the last 12 months.

RCUS's Price Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as ATXS (93) in the Biotechnology industry. This means that RCUS’s stock grew similarly to ATXS’s over the last 12 months.

RCUS's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSRCUS
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMRGX7.20N/A
N/A
American Growth One D
WENRX54.17N/A
N/A
Allspring Mid Cap Growth Fund - Cl R6
MITHX35.23N/A
N/A
MFS Massachusetts Investors Tr R3
GGEYX25.77N/A
N/A
GuideStone Funds Growth Equity Instl
RVPIX7.20-0.29
-3.87%
Royce Smaller-Companies Growth Instl

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with KYMR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-5.82%
KYMR - ATXS
48%
Loosely correlated
+0.40%
DNLI - ATXS
47%
Loosely correlated
-10.43%
CRNX - ATXS
46%
Loosely correlated
+1.41%
ABOS - ATXS
45%
Loosely correlated
-4.00%
IMNM - ATXS
45%
Loosely correlated
-5.14%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with ACLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-1.77%
ACLX - RCUS
45%
Loosely correlated
+1.95%
ATXS - RCUS
39%
Loosely correlated
-5.82%
AMLX - RCUS
39%
Loosely correlated
-9.82%
ITOS - RCUS
39%
Loosely correlated
-1.28%
AXON - RCUS
39%
Loosely correlated
-2.08%
More